Internal Medicine, Endocrinology, Diabetes, & Metabolism · Dallas, TX
NPI
1629331400
Since 2012
Specialty
Internal Medicine, Endocrinology, Diabetes, & Metabolism
Code 207RE0101X
Group practices
1
Medicare group memberships
Hospitals
1
Hospital affiliations
2001 Inwood Rd, West Campus Building 3
Dallas, TX, 75390
Phone (214) 645-2800
Groups this clinician bills Medicare through
Medicare paid, 2024
$28K
282 services
Medicare patients, 2024
137
Average age 69
Drug cost, 2024
$1.6M
933 prescriptions
Company payments, 2025
$80K
From 5 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Oksana Hamidi was code 99215 (office e&m - established), 139 times for 84 patients. In total Oksana Hamidi billed 282 services in 14 codes, and Medicare paid $28K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2019-05-15.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99215 Office E&M - Established | Office | 139 | 84 | $134.54 | $19K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 46 | 28 | $12.32 | $567 |
| 99214 Office E&M - Established | Office | 39 | 37 | $89.82 | $3,503 |
| 99205 Office E&M - New | Office | 17 | 17 | $165.27 | $2,810 |
By year: 2022 $22K for 209 services; 2023 $23K for 214 services; 2024 $28K for 282 services.
Medicare prescription drug claims, 2024
In 2024, the drug Oksana Hamidi prescribed most often to Medicare patients was Hydrocortisone, with 167 prescriptions and refills. In total Oksana Hamidi wrote 933 Medicare prescriptions that cost $1.6M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Hydrocortisone Generic | 167 | 338 | 49 | $9,873 |
| Levothyroxine Sodium Generic | 74 | 208 | 29 | $829 |
| Mounjaro Tirzepatide | 51 | 56 | Under 11 | $58K |
| Synthroid Levothyroxine Sodium | 34 | 78 | Under 11 | $2,400 |
| Fludrocortisone Acetate Generic | 32 | 65 | 11 | $434 |
| Testosterone Generic | 31 | 32 | Under 11 | $4,906 |
| Jardiance Empagliflozin | 28 | 72 | Under 11 | $42K |
| Lysodren Mitotane | 28 | 28 | Under 11 | $65K |
| Ozempic Semaglutide | 24 | 28 | Under 11 | $27K |
| Atorvastatin Calcium Generic | 24 | 68 | Under 11 | $164 |
| Isturisa Osilodrostat Phosphate | 24 | 24 | Under 11 | $1.3M |
| Solu-Cortef Hydrocortisone Sodium Succ/Pf | 22 | 22 | 16 | $762 |
| Spironolactone Generic | 22 | 58 | Under 11 | $542 |
| Dexamethasone Generic | 21 | 21 | 18 | $47.29 |
| Doxazosin Mesylate Generic | 18 | 32 | Under 11 | $259 |
Brand drugs: - claims; generic drugs: 568 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Oksana Hamidi $80K ($25K in general payments such as food, travel and fees and $56K for research) from 5 companies. The largest payer was Neurocrine BioSciences, Inc. with $62K.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.